Previous 10 | Next 10 |
The following slide deck was published by ZIOPHARM Oncology, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: ZIOPHARM Oncology, Inc. 2020 Q4 - Results - Earnings Call Presentation
ET ZIOPHARM Oncology, Inc. (ZIOP) Q4 2020 Earnings Conference Call February 25, 2021, 04:30 PM ET Company Participants Adam Levy - Executive Vice President, Investor Relations and Corporate Laurence Cooper - Chief Executive Officer Heidi Hagen - Interim Chief Executive Officer Raffaele Baffa ...
Heidi Hagen Appointed Interim Chief Executive Officer Replacing Dr. Laurence Cooper; Search for Permanent CEO Initiated Dr. Laurence Cooper Expected to Continue with Company in a Scientific Advisory Role James Huang Appointed Executive Chairman and Board Refreshment Comp...
ZIOPHARM Oncology (NASDAQ:ZIOP) is scheduled to announce Q4 earnings results on Thursday, February 25th, after market close.The consensus EPS Estimate is -$0.10Over the last 2 years, ZIOP has beaten EPS estimates 25% of the time and has beaten revenue estimates 13% of the time. For further ...
Palm Beach, FL – February 18, 2021 – Ovarian cancer and its rising incidence rate is a growing concern worldwide and the rising incidence of ovarian cancer will be driving the ovarian cancer drugs market for years to come. Ovarian cancer is regarded as one of the most common t...
BOSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (the “Company”) (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast to discuss financial results for the fourth quarter and full year 2020 on Thursday, February 25, 2021 at 4:30pm...
Ziopharm Oncology (ZIOP) has announced the election of Robert Postma to its Board of Directors effective immediately. The stock has added 11.6% so far today after a gain of ~12.2% yesterday.Laurence Cooper, CEO of Ziopharm, said, “We will benefit from having additio...
Shares of Ziopharm Oncology (NASDAQ: ZIOP) were soaring 11.8% as of 11:45 a.m. EST on Friday. The nice gain came after the company announced the election of Robert Postma to its board of directors. The addition expanded Ziopharm's board from eight members to nine. The election o...
BOSTON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Board”), effective immediately. Mr. Postma is the Founde...
The following slide deck was published by ZIOPHARM Oncology, Inc. in conjunction with this event. For further details see: Ziopharm Oncology (ZIOP) Presents at J.P. Morgan Healthcare Conference 2021 - Slideshow
News, Short Squeeze, Breakout and More Instantly...
ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...